Skip to main content
. 2022 Nov 21;324(1):G60–G77. doi: 10.1152/ajpgi.00112.2022

Figure 3.

Figure 3.

Apical sodium bile acid (BA) transporter (ASBT) Vivo-Morpholino (VM) reduces hepatic inflammation, biliary senescence-associated secretory phenotype (SASP) secretion, and histamine serum content. There was increased Kupffer cell presence (F4/80) (A) with semiquantification and macrophage inflammatory protein-1α/C-C motif ligand 3 (MIP1-α/CCL3) secretion from isolated cholangiocyte supernatant (B) in multidrug-resistant 2 knockout (Mdr2−/−) Control mice compared with wild-type (WT) mice. ASBT VM treatment reduced hepatic inflammation and biliary MIP1-α/CCL3 in Mdr2−/− mice (A and B). Serum histamine content increased in Mdr2−/− Control compared with WT mice but was reduced after ASBT VM treatment (C). Representative images are presented as ×10 for F4/80. Data are presented as mean ± SD of n = 5 images for F4/80 quantification from 7–10 mice per group. Data are presented as mean ± SD of 4 technical replicates for histamine enzyme immunoassay (EIA) and 3 technical replicates for biliary MIP1-α/CCL3 secretion pooled from 7 to 10 mice per group. *P < 0.05, **P < 0.01, ****P < 0.0001.